Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
3',5'-cyclic-AMP phosphodiesterase 4A (PDE4A) is an enzyme that hydrolyzes the second messenger cyclic adenosine monophosphate (cAMP), a key regulator of numerous physiological processes. By breaking down cAMP, PDE4A plays a central role in modulating cellular responses to extracellular signals and maintaining cellular homeostasis. PDE4A is a therapeutic target, specifically isoforms 1, 2, 6, and 7, with inhibitors being explored or used for conditions like depression and chronic inflammatory diseases due to their ability to modulate immune cell function and neuronal signaling.
Inhibition of cAMP hydrolysis, leading to increased intracellular cAMP levels.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 3',5'-cyclic-AMP phosphodiesterase 4A (PDE4A).